High Tower Advisors, LLC Coherus Bio Sciences, Inc. Transaction History

High Tower Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$15.81 - $18.99 $186,162 - $223,607	-11,775 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$12.68 - $17.79 $4,121 - $5,781	325 Added 2.84%	11,775 $189,000
Q2 2020 Aug 10, 2020	SELL	$14.43 - $19.16 $1,154 - $1,532	-80 Reduced 0.69%	11,450 $205,000
Q1 2020 May 21, 2020	BUY	$11.67 - $22.53 $70 - $135	6 Added 0.05%	11,530 $185,000
Q4 2019 Feb 14, 2020	SELL	$16.33 - $21.37 $25,213 - $32,995	-1,544 Reduced 11.82%	11,524 $207,000
Q3 2019 Nov 12, 2019	BUY	$16.3 - $23.37 $14,409 - $20,659	884 Added 7.26%	13,068 $264,000
Q2 2019 Aug 13, 2019	BUY	$13.1 - $22.1 $9,615 - $16,221	734 Added 6.41%	12,184 $268,000
Q4 2018 Feb 14, 2019	BUY	$8.65 - $16.28 $9,515 - $17,908	1,100 Added 10.63%	11,450 $104,000
Q1 2018 May 15, 2018	BUY	$9.1 - $13.7 $94,185 - $141,795	10,350 New	10,350 $114,000

132

76.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $91.7M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on High Tower Advisors, LLC with notifications on news.